PetVivo Holdings, Inc., a veterinary biotech and biomedical device company, engages in the licensing and commercializing of medical devices and biomaterials for the treatment of afflictions and diseases in animals. Its lead product is Kush, a veterinarian-administered joint injection for the treatment of osteoarthritis and lameness in dogs and horses. The company's pipeline products include 17 therapeutic devices for veterinary and human clinical applications. PetVivo Holdings, Inc. is headquartered in Minneapolis, Minnesota.
IPO Year:
Exchange: NASDAQ
Website: petvivo.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 10/12/2021 | $7.00 | Buy | ThinkEquity |
MINNEAPOLIS, MN, Oct. 21, 2024 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc. (OTCQB:PETV, PETVW))), a leading provider of biomedical therapeutics for equines and companion animals, has appointed Cindy Gill to the position of field veterinary business development manager for the entire states of Oklahoma and Arkansas and the northern region of Texas. "Cindy's experience and strong record of sales achievement with veterinary clinics brings to our sales team a valuable resource for achieving our business goals," PetVivo CEO, John Lai. "Her experience with other veterinary products and her knowledge of clinic operations enables her to prioritize and better address the veterinarians and cli
MINNEAPOLIS, MN, Sept. 16, 2024 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc. (OTCQB:PETV, PETVW))), a leading provider of biomedical therapeutics for equines and companion animals, has appointed Skylor Walker to the new position of field veterinary business development manager for the entire state of Louisiana and the southern region of Texas. "Skylor's experience and strong record of sales achievement with veterinary clinics brings to our sales team a valuable resource for achieving our business goals," PetVivo CEO, John Lai. "Her experience with other hydrogel injectable products enables us to prioritize and better address the veterinarians and clinics in our sales pipeline."
Expert Capablites of Senior Vet-Tech to Help Drive Greater Adoption of Spryng as Breakthrough Treatment of Osteoarthritis for Companiaon Animals MINNEAPOLIS, MN, & Annapolis Junction, MD, US, Sept. 09, 2024 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc. (OTCQB:PETV, PETVW))), a leading biomedical company delivering innovative therapeutic devices for equines and companion animals, has appointed board certified veterinary surgeon, Dr. Kirsty Husby, DVM, MS, DACVS (LA), to the position of senior technical services veterinarian. Dr. Husby brings to PetVivo more than a decade of experience and accomplishment in animal health. This has involved clinical practice and research experience at
MINNEAPOLIS, MN, US, Aug. 19, 2024 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc. (OTCB: PETV & PETVW) (the "Company") an emerging biomedical device company focused on the commercialization of innovative medical devices and therapeutics for companion animals and animal athletes is pleased to announce that Anthony Germinaro has accepted a position with the Company as its new Field Veterinary Business Development Manager for the for the Southwest Region of the United States. "Adding Anthony to our sales and distribution team provides a tremendous boost to PetVivo's commercialization efforts," said John Lai, Chief Executive Officer of PetVivo Holdings, Inc. "Anthony brings to PetVivo a wealth of
MINNEAPOLIS, MN, US, Aug. 12, 2024 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc. (OTCQB:PETV, PETVW))) (the "Company") an emerging biomedical device company focused on the commercialization of innovative medical devices and therapeutics for companion animals and animal athletes is pleased to announce that Eric Samples has accepted a position with the Company as its new Field Veterinary Business Development Manager to cover Ohio, Pennsylvania, and the Baltimore/DC area of the United States. "We are incredibly excited to add Eric to our sales and distribution team," said John Lai, Chief Executive Officer of PetVivo Holdings, Inc. "The experience Eric brings to PetVivo is extraordinarily va
MINNEAPOLIS, MN, US, June 06, 2024 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc. (OTC:PETV, PETVW))), a leading biomedical company delivering innovative therapeutic medical devices for equines and companion animals, has appointed Bryan Monninger to vice president of sales. In this new position, he will lead the PetVivo's sales and distribution teams, with a focus on expanding the market adoption of the company's innovative animal osteoarthritis medical product, Spryng™ with OsteoCushion™ Technology. Monninger brings to PetVivo more than 20 years of experience in sales and marketing, including senior executive positions at NOVUS and Lintbells, and the Fo
MINNEAPOLIS, MN, US, June 04, 2024 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc. (OTC:PETV, PETVW))) (the "Company") an emerging biomedical device company focused on the commercialization of innovative medical devices and therapeutics for companion animals is pleased to announce that April Boyce has accepted a position with the Company as its new Vice President of Marketing. "We are thrilled to have April join the PetVivo team and apply her vast insight and expertise to introduce and enhance the overall awareness and image of PetVivo and the products PetVivo commercializes." said John Lai, Chief Executive Officer of PetVivo Holdings, Inc. "April brings a wealth of experience to our team as
MINNEAPOLIS, MN, US, March 11, 2024 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc. (NASDAQ:PETV, PETVW))) (the "Company") an emerging biomedical device company focused on the commercialization of innovative medical devices and therapeutics for companion animals and animal athletes is pleased to announce that Garry Lowenthal has accepted a position with the Company as its new Chief Financial Officer. "We are incredibly excited to have Garry join the PetVivo management team and provide his well-recognized expertise to further the overall mission of PetVivo." said John Lai, Chief Executive Officer of PetVivo Holdings, Inc. "Mr. Lowenthal brings a wealth of experience to our team as an expert i
4 - PetVivo Holdings, Inc. (0001512922) (Issuer)
ThinkEquity initiated coverage of PetVivo Holdings with a rating of Buy and set a new price target of $7.00
10-Q - PetVivo Holdings, Inc. (0001512922) (Filer)
8-K - PetVivo Holdings, Inc. (0001512922) (Filer)
8-K - PetVivo Holdings, Inc. (0001512922) (Filer)
8-K - PetVivo Holdings, Inc. (0001512922) (Filer)
8-K - PetVivo Holdings, Inc. (0001512922) (Filer)
25-NSE - PetVivo Holdings, Inc. (0001512922) (Subject)
10-Q - PetVivo Holdings, Inc. (0001512922) (Filer)
8-K - PetVivo Holdings, Inc. (0001512922) (Filer)
8-K - PetVivo Holdings, Inc. (0001512922) (Filer)
10-K/A - PetVivo Holdings, Inc. (0001512922) (Filer)
4/A - PetVivo Holdings, Inc. (0001512922) (Issuer)
4/A - PetVivo Holdings, Inc. (0001512922) (Issuer)
4/A - PetVivo Holdings, Inc. (0001512922) (Issuer)
4/A - PetVivo Holdings, Inc. (0001512922) (Issuer)
4/A - PetVivo Holdings, Inc. (0001512922) (Issuer)
4/A - PetVivo Holdings, Inc. (0001512922) (Issuer)
4 - PetVivo Holdings, Inc. (0001512922) (Issuer)
4 - PetVivo Holdings, Inc. (0001512922) (Issuer)
4 - PetVivo Holdings, Inc. (0001512922) (Issuer)
4 - PetVivo Holdings, Inc. (0001512922) (Issuer)
SC 13G/A - PetVivo Holdings, Inc. (0001512922) (Subject)
SC 13G - PetVivo Holdings, Inc. (0001512922) (Subject)
SC 13G/A - PetVivo Holdings, Inc. (0001512922) (Subject)
SC 13G - PetVivo Holdings, Inc. (0001512922) (Subject)
SC 13G/A - PetVivo Holdings, Inc. (0001512922) (Subject)
SC 13D/A - PetVivo Holdings, Inc. (0001512922) (Subject)
SC 13G/A - PetVivo Holdings, Inc. (0001512922) (Subject)
SC 13G/A - PetVivo Holdings, Inc. (0001512922) (Subject)
SC 13G/A - PetVivo Holdings, Inc. (0001512922) (Subject)
SC 13D - PetVivo Holdings, Inc. (0001512922) (Subject)
MINNEAPOLIS, MN, US, Nov. 14, 2024 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc. (OTCQB:PETV, PETVW)), a leading biomedical company delivering innovative therapeutic medical devices for equines and companion animals, reported results for the fiscal second quarter ended September 30, 2024. All comparisons are to the same year-ago period unless otherwise noted. The company will hold a conference call at 5:00 p.m. Eastern time November 14, 2024 to discuss the results (see dial-in information below). Fiscal Q2 2025 Financial Highlights Revenues totaled $201,000, up 62% sequentially and down 3% from the same year ago period, as the company continued to transition in the current fiscal yea
MINNEAPOLIS, MN, US, Nov. 11, 2024 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc. (OTCQB:PETV), an emerging biomedical device company focused on the commercialization of innovative medical therapeutics for animals, will report financial results on Thursday, November 14, 2024 after market close. The company will host a conference call to discuss these results at 4:00 p.m. CT (5:00 p.m. ET) on the same day. Attendees of the live webcast of the conference call and related earnings release materials can register and access the webcast on PetVivo's Investor Relations website at: https://audience.mysequire.com/webinar-view?webinar_id=6fd4ce0f-76b5-4819-9fd7-a8412e31847e A replay of the webcast wi
MINNEAPOLIS, MN, Oct. 21, 2024 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc. (OTCQB:PETV, PETVW))), a leading provider of biomedical therapeutics for equines and companion animals, has appointed Cindy Gill to the position of field veterinary business development manager for the entire states of Oklahoma and Arkansas and the northern region of Texas. "Cindy's experience and strong record of sales achievement with veterinary clinics brings to our sales team a valuable resource for achieving our business goals," PetVivo CEO, John Lai. "Her experience with other veterinary products and her knowledge of clinic operations enables her to prioritize and better address the veterinarians and cli
MINNEAPOLIS, MN, Sept. 16, 2024 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc. (OTCQB:PETV, PETVW))), a leading provider of biomedical therapeutics for equines and companion animals, has appointed Skylor Walker to the new position of field veterinary business development manager for the entire state of Louisiana and the southern region of Texas. "Skylor's experience and strong record of sales achievement with veterinary clinics brings to our sales team a valuable resource for achieving our business goals," PetVivo CEO, John Lai. "Her experience with other hydrogel injectable products enables us to prioritize and better address the veterinarians and clinics in our sales pipeline."
Expert Capablites of Senior Vet-Tech to Help Drive Greater Adoption of Spryng as Breakthrough Treatment of Osteoarthritis for Companiaon Animals MINNEAPOLIS, MN, & Annapolis Junction, MD, US, Sept. 09, 2024 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc. (OTCQB:PETV, PETVW))), a leading biomedical company delivering innovative therapeutic devices for equines and companion animals, has appointed board certified veterinary surgeon, Dr. Kirsty Husby, DVM, MS, DACVS (LA), to the position of senior technical services veterinarian. Dr. Husby brings to PetVivo more than a decade of experience and accomplishment in animal health. This has involved clinical practice and research experience at
MINNEAPOLIS, MN, US, Sept. 03, 2024 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc. (OTCQB:PETV, PETVW))) (the "Company") an emerging biomedical device company focused on the commercialization of innovative medical devices and therapeutics for companion animals and animal athletes is pleased to announce that Scot Cave has accepted a position with the Company as its new Field Veterinary Business Development Manager to cover the Northwest Region of the United States. "The addition of Scot to our sales and distribution team provides our company a wealth of leadership and veterinary sales experience," said John Lai, Chief Executive Officer of PetVivo Holdings, Inc. "One of our primary object
Orthobiologic President & CEO, Sherman O. Canapp, Jr. and Director of Diagnositcs and Education, Debra Cannap, Join PetVivo Advisory Board MINNEAPOLIS, MN, & Annapolis Junction, MD, US, Aug. 27, 2024 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc. (OTCQB:PETV, PETVW))), a leading biomedical company delivering innovative therapeutic medical devices for equines and companion animals, has teamed up with Orthobiologic Innovations ("OBI"), in R&D for regenerative and sports medicine, to pursue new clinical trials, product development and marketing of the company's lead animal osteoarthritis medical device, Spryng™ with OsteoCushion™ Technology. OBI president and CEO and past presid
MINNEAPOLIS, MN, US, Aug. 19, 2024 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc. (OTCB: PETV & PETVW) (the "Company") an emerging biomedical device company focused on the commercialization of innovative medical devices and therapeutics for companion animals and animal athletes is pleased to announce that Anthony Germinaro has accepted a position with the Company as its new Field Veterinary Business Development Manager for the for the Southwest Region of the United States. "Adding Anthony to our sales and distribution team provides a tremendous boost to PetVivo's commercialization efforts," said John Lai, Chief Executive Officer of PetVivo Holdings, Inc. "Anthony brings to PetVivo a wealth of
Company Reieterates Gudience of 50% to 100% Revenue Growth in Fiscal 2025 MINNEAPOLIS, MN, US, Aug. 14, 2024 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc. (OTCQB:PETV, PETVW))), a leading biomedical company delivering innovative therapeutic medical devices for equines and companion animals, reported results for the fiscal first quarter ended June 30, 2024. All comparisons are to the same year-ago period unless otherwise noted. The company will hold a conference call at 5:00 p.m. Eastern time August 14, 2024 to discuss the results (see dial-in information below). Fiscal Q1 2025 Financial Highlights Revenues increased 6% to $124,000, driven by the increasing roll out and adoption of
MINNEAPOLIS, MN, US, Aug. 12, 2024 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc. (OTCQB:PETV, PETVW))) (the "Company") an emerging biomedical device company focused on the commercialization of innovative medical devices and therapeutics for companion animals and animal athletes is pleased to announce that Eric Samples has accepted a position with the Company as its new Field Veterinary Business Development Manager to cover Ohio, Pennsylvania, and the Baltimore/DC area of the United States. "We are incredibly excited to add Eric to our sales and distribution team," said John Lai, Chief Executive Officer of PetVivo Holdings, Inc. "The experience Eric brings to PetVivo is extraordinarily va
MINNEAPOLIS, MN, US, Nov. 14, 2024 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc. (OTCQB:PETV, PETVW)), a leading biomedical company delivering innovative therapeutic medical devices for equines and companion animals, reported results for the fiscal second quarter ended September 30, 2024. All comparisons are to the same year-ago period unless otherwise noted. The company will hold a conference call at 5:00 p.m. Eastern time November 14, 2024 to discuss the results (see dial-in information below). Fiscal Q2 2025 Financial Highlights Revenues totaled $201,000, up 62% sequentially and down 3% from the same year ago period, as the company continued to transition in the current fiscal yea
MINNEAPOLIS, MN, US, Nov. 11, 2024 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc. (OTCQB:PETV), an emerging biomedical device company focused on the commercialization of innovative medical therapeutics for animals, will report financial results on Thursday, November 14, 2024 after market close. The company will host a conference call to discuss these results at 4:00 p.m. CT (5:00 p.m. ET) on the same day. Attendees of the live webcast of the conference call and related earnings release materials can register and access the webcast on PetVivo's Investor Relations website at: https://audience.mysequire.com/webinar-view?webinar_id=6fd4ce0f-76b5-4819-9fd7-a8412e31847e A replay of the webcast wi
Company Reieterates Gudience of 50% to 100% Revenue Growth in Fiscal 2025 MINNEAPOLIS, MN, US, Aug. 14, 2024 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc. (OTCQB:PETV, PETVW))), a leading biomedical company delivering innovative therapeutic medical devices for equines and companion animals, reported results for the fiscal first quarter ended June 30, 2024. All comparisons are to the same year-ago period unless otherwise noted. The company will hold a conference call at 5:00 p.m. Eastern time August 14, 2024 to discuss the results (see dial-in information below). Fiscal Q1 2025 Financial Highlights Revenues increased 6% to $124,000, driven by the increasing roll out and adoption of
MINNEAPOLIS, MN, US, Aug. 08, 2024 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc. (OTCQB:PETV, PETVW))), a leading biomedical company delivering innovative therapeutic medical devices for equines and companion animals, will hold a conference call on Wednesday, August 14, 2024 at 5:00 p.m. Eastern time to discuss results for the fiscal first quarter ended June 30, 2024. The financial results will be issued in a press release prior to the call. PetVivo management will host the presentation, followed by a question-and-answer period. Date: Wednesday, August 14, 2024Time: 5:00 p.m. Eastern time (2:00 p.m. Pacific time)Toll-free dial-in number: 1-253-215-8782Conference ID: 85913290613Passcode: 187
MINNEAPOLIS, MN, US, June 28, 2024 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc. (OTC:PETV, PETVW))), a leading biomedical company delivering innovative therapeutic medical devices for equines and companion animals, reported results for the fiscal year ended March 31, 2024. All comparisons are to the same year-ago period unless otherwise noted. The company will hold a conference call at 5:00 p.m. Eastern time today to discuss the results (see dial-in information below). Fiscal 2024 Financial Highlights Revenues up 6% to $969,000, driven sales of the company's lead veterinary medical device, Spryng™ with OsteoCushion™ technology.Revenue growth was driven largely by the company's expa
MINNEAPOLIS, MN, US, June 25, 2024 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc. (OTC:PETV, PETVW))), a leading biomedical company delivering innovative therapeutic medical devices for equines and companion animals, will hold a conference call on Friday, June 28, 2024 at 5:00 p.m. Eastern time to discuss results for the fiscal fourth quarter and year ended March 31, 2024. The financial results will be issued in a press release prior to the call. PetVivo management will host the presentation, followed by a question-and-answer period. Date: Friday, June 28, 2024Time: 5:00 p.m. Eastern time (2:00 p.m. Pacific time)Toll-free dial-in number: 1-719-359-4580Conference ID: 845 8120 3778Passcode
Conference call begins at 4:00 p.m. Central time today EDINA, MN, Feb. 12, 2024 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc. (NASDAQ:PETV), an emerging biomedical device company focused on the commercialization of innovative medical therapeutics for animals, announces financial results for the three months ended December 31, 2023 ("third quarter of 2024"). Key highlights from the third quarter of 2024 and through February 12, 2024, include the following: Developed a multi-distribution sales strategy, including entering into non-exclusive distribution agreements with Covetrus North America LLC and MW Veterinary Supply Co.;Added a new Board member, Diane Levitan, who is a licensed vet
MINNEAPOLIS, MN, US, Feb. 06, 2024 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc. (NASDAQ:PETV), an emerging biomedical device company focused on the commercialization of innovative medical therapeutics for animals, will report financial results on Monday, February 12, 2024 after market close. The company will host a conference call to discuss these results at 4:00 p.m. CT (5:00 p.m. ET) on the same day. Attendees of the live webcast of the conference call and related earnings release materials can register and access the webcast on PetVivo's Investor Relations website at: https://audience.mysequire.com/webinar-view?webinar_id=aabb88e0-5162-4f89-8aaf-69e333b45beb A replay of the webcast wil
MINNEAPOLIS, MN, US, Nov. 09, 2023 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc. (NASDAQ:PETV), an emerging biomedical device company focused on the commercialization of innovative medical therapeutics for animals, will report financial results on Tuesday, November 14, 2023 after market close. The company will host a conference call to discuss these results at 4:00 p.m. CT (5:00 p.m. ET) on the same day. Attendees of the live webcast of the conference call and related earnings release materials can register and access the webcast on PetVivo's Investor Relations website at: https://audience.mysequire.com/webinar-view?webinar_id=13014345-4054-48e0-b0d9-f0b425d9e51c A replay of the webcast wi
MINNEAPOLIS, MN, US, Aug. 07, 2023 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc. (NASDAQ:PETV), an emerging biomedical device company focused on the commercialization of innovative medical therapeutics for animals, will report financial results on Thursday, August 10, 2023 after market close. The company will host a conference call to discuss these results at 4:00 p.m. CT (5:00 p.m. ET) on the same day. Attendees of the live webcast of the conference call and related earnings release materials can register and access the webcast on PetVivo's Investor Relations website at: https://audience.mysequire.com/webinar-view?webinar_id=7982d224-6a39-4cd3-800a-51ceb97d772c A replay of the webca
The Dow Jones index closed lower by around 0.1% on Wednesday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision. Below is a look at a few recent notable insider transactions for penny stocks. For more, check out Benzinga's insider transactions platform. IZEA Worldwide The Trade: IZEA Worldwide, Inc. (NASDAQ:IZEA) 10% owner GP Cash Management Ltd acquired a total of 7,136 shares an average price of $2.50. To acquire these shares, it cost around $17,840. What’s Happening: On April 1, IZEA Worldwide
Gainers Kineta (NASDAQ:KA) shares increased by 24.3% to $0.67 during Monday's after-market session. The market value of their outstanding shares is at $7.3 million. Moleculin Biotech (NASDAQ:MBRX) stock increased by 10.21% to $5.6. The company's market cap stands at $12.4 million. Cue Health (NASDAQ:HLTH) stock moved upwards by 6.01% to $0.18. The market value of their outstanding shares is at $29.3 million. Nexalin Technology (NASDAQ:NXL) shares moved upwards by 5.57% to $2.46. The company's market cap stands at $18.2 million. Atara Biotherapeutics (NASDAQ:ATRA) stock moved upwards by 5.52% to $0.8. The market value of their outstanding shares is at $95.2 million. PetVivo Hldgs (NASDA
Gainers Longeveron (NASDAQ:LGVN) shares moved upwards by 75.0% to $3.85 during Monday's pre-market session. The market value of their outstanding shares is at $9.6 million. PetVivo Hldgs (NASDAQ:PETV) stock increased by 17.09% to $1.22. The company's market cap stands at $20.4 million. SHL Telemedicine (NASDAQ:SHLT) stock moved upwards by 13.26% to $6.49. The company's market cap stands at $106.3 million. Pluri (NASDAQ:PLUR) stock moved upwards by 12.02% to $6.15. The market value of their outstanding shares is at $32.1 million. Novo Integrated Sciences (NASDAQ:NVOS) shares moved upwards by 11.35% to $0.5. The company's market cap stands at $8.8 million. Ocugen (NASDAQ:OCGN) stock move
- SEC FilingPetVivo Holdings, Inc. (the "Company") and ThinkEquity, LLC mutually agreed to terminate the ATM Sales Agreement, dated as of August 23, 2023 (the "ATM Agreement") between the Company and with ThinkEquity LLC (the "Agent"), effective as of March 7, 2024. Subject to the terms and conditions of the ATM Agreement, the Company could from time to time offer and sell shares of the Company's common stock having an aggregate offering price of up to $2,500,000 through the Agent in "at-the-market offerings" as defined in Rule 415 of the Securities Act of 1933, as amended. Prior to termination, the Company issued and sold 674,000 shares of its common stock under the ATM Agreement, raising n
PetVivo Holdings, Inc. (NASDAQ:PETV, PETVW))))) (the "Company") an emerging biomedical device company focused on the commercialization of innovative medical devices and therapeutics for companion animals and animal athletes is pleased to announce that Garry Lowenthal has accepted a position with the Company as its new Chief Financial Officer."We are incredibly excited to have Garry join the PetVivo management team and provide his well-recognized expertise to further the overall mission of PetVivo." said John Lai, Chief Executive Officer of PetVivo Holdings, Inc. "Mr. Lowenthal brings a wealth of experience to our team as an expert in leading the operations and finances of numerous private an
Companies Reporting Before The Bell • Beasley Broadcast Group (NASDAQ:BBGI) is projected to report quarterly loss at $0.07 per share on revenue of $66.05 million. • Trimble (NASDAQ:TRMB) is likely to report quarterly earnings at $0.59 per share on revenue of $911.34 million. • Monday.Com (NASDAQ:MNDY) is estimated to report quarterly earnings at $0.32 per share on revenue of $197.95 million. • Alexander's (NYSE:ALX) is projected to report earnings for its fourth quarter. Companies Reporting After The Bell • Cemtrex (NASDAQ:CETX) is estimated to report earnings for its first quarter. • Star Bulk Carriers (NASDAQ:SBLK) is projected to report quarterly earnings at $0.73 per share on reve
PetVivo Holdings, Inc. (NASDAQ:PETV, PETVW))))) (the "Company" or "PetVivo") an emerging biomedical device company focused on the commercialization of innovative medical devices and therapeutics for companion animals announced that the Company has released the results of a clinical study conducted by Inotiv, Inc., a world-renowned independent clinical research organization, which examined the safety of intra-articular injections of collagen-elastin hydrogel microparticulates (i.e. Spryng™ with OsteoCushion™ Technology) into the joints of cats. "We are pleased to have the release of the final results of this Spryng tolerance study as this data demonstrates the safety of our veterinary medical